Bispecific immunotherapy for viral infections

Eradivir is pioneering innovative therapeutic approaches that leverage the body's immune system to combat diseases, particularly viral infections and cancer. Central to their strategy is the development of Bispecific Antigenic immuno-Therapy (BAiT) technology, which utilizes small molecules to bind specifically to diseased cells. This mechanism acts as a beacon, effectively guiding immune cells to target and destroy these cells with precision. By employing this targeted approach, Eradivir aims to create a versatile toolkit of immunotherapies that can address a range of diseases, enhancing the efficacy of treatments and potentially leading to cures.

One of the company's notable advancements is their lead molecule, EV25, which has demonstrated superior effectiveness compared to existing treatments for influenza. EV25 operates by linking infected cells to two anti-hapten antibodies, thereby enlisting the innate immune system to swiftly eliminate the virus. This innovative method not only highlights Eradivir's commitment to rethinking traditional treatment paradigms but also underscores their focus on developing therapies that harness the body's natural defenses to achieve better health outcomes.

United States

Eradivir is a biotech company that aims to develop a non-immunological targeting agent for use against the virus that causes COVID-19. The company has discovered small bispecific drugs that engage both cytotoxic immune cells and the virus. Binding of the drug to the virus leads to the destruction of the virus by the immune system.

Eradivir

Company Details